A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia 2021 Oct;35(10):2994-2997
Date
05/05/2021Pubmed ID
33941850DOI
10.1038/s41375-021-01256-8Scopus ID
2-s2.0-85105147190 (requires institutional sign-in at Scopus site) 7 CitationsAuthor List
Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo MAuthor
Paul D. Harker-Murray MD, PhD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Anthracyclines
Antineoplastic Combined Chemotherapy Protocols
Child
Child, Preschool
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Lymphoma, B-Cell
Male
Prognosis
Rituximab
Survival Rate
Young Adult
